IRLA · IRulya Therapeutics Inc.
AI read · Good for IRLA
The AI's read
The cash gives IRulya time to run its studies without needing to raise more money soon, based on the company’s estimate. The concern is its quarterly loss more than doubled, and office costs rose. Still, the cash is expected to cover the planned studies, so the update leans positive.